Target Name: PTPN4
NCBI ID: G5775
Review Report on PTPN4 Target / Biomarker Content of Review Report on PTPN4 Target / Biomarker
PTPN4
Other Name(s): MEG | protein tyrosine phosphatase MEG1 | protein tyrosine phosphatase non-receptor type 4 | Megakaryocyte phosphatase | Protein tyrosine phosphatase MEG1 | Tyrosine-protein phosphatase non-receptor type 4 | PTPase-MEG1 | Protein tyrosine phosphatase, non-receptor type 4 (PTPN4) | Protein tyrosine phosphatase non-receptor type 4 | megakaryocyte protein-tyrosine phosphatase | megakaryocyte phosphatase | Megakaryocyte protein-tyrosine phosphatase | Protein-tyrosine phosphatase MEG1 | PTN4_HUMAN | protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte) | PTPMEG1 | PTPMEG

Regulation of Neuronal Excitability and Synaptic Plasticity By PTPN4

PTPN4 (poly (thiomarginal) phosphate neurotransmitter) is a protein that is expressed in the central nervous system (CNS) and is involved in the regulation of neuronal excitability. It is a key player in the intracellular signaling pathway known as the TGF-β pathway, which is involved in the development, maintenance, and regulation of neural circuits.

The TGF-β pathway is a well-established mechanism for the development and maintenance of neural circuits, and is involved in the regulation of a wide range of physiological processes, including neuronal excitability and synaptic plasticity. The PTPN4 protein is a key regulator of this pathway, and is involved in the regulation of neuronal excitability and synaptic plasticity.

Studies have shown that PTPN4 plays a critical role in the regulation of neuronal excitability and synaptic plasticity. PTPN4 is involved in the regulation of action potential (AP) generation and propagation, as well as the regulation of neurotransmitter release and synaptic plasticity.

In addition to its role in the regulation of neuronal excitability and synaptic plasticity, PTPN4 is also involved in the regulation of other physiological processes, including cell survival and metabolism.

Given its involvement in the regulation of neural circuits, PTPN4 is a potential drug target for the treatment of a wide range of neurological and psychiatric disorders. Studies have shown that PTPN4 is highly expressed in the brain and that its levels are often decreased in the brains of individuals with neuropsychiatric disorders.

In addition to its potential clinical applications, PTPN4 is also a potential biomarker for the diagnosis and prognosis of neuropsychiatric disorders. Studies have shown that PTPN4 levels are often decreased in the brains of individuals with neuropsychiatric disorders, and that these levels can be increased by pharmacological intervention.

Overall, PTPN4 is a protein that is involved in the regulation of neuronal excitability and synaptic plasticity, and is a potential drug target and biomarker for the treatment of neuropsychiatric disorders. Further research is needed to fully understand the role of PTPN4 in neural circuits and the potential applications of this protein.

Protein Name: Protein Tyrosine Phosphatase Non-receptor Type 4

Functions: Phosphatase that plays a role in immunity, learning, synaptic plasticity or cell homeostasis (PubMed:25825441, PubMed:27246854). Regulates neuronal cell homeostasis by protecting neurons against apoptosis (PubMed:20086240). Negatively regulates TLR4-induced interferon beta production by dephosphorylating adapter TICAM2 and inhibiting subsequent TRAM-TRIF interaction (PubMed:25825441). Dephosphorylates also the immunoreceptor tyrosine-based activation motifs/ITAMs of the TCR zeta subunit and thereby negatively regulates TCR-mediated signaling pathway (By similarity). May act at junctions between the membrane and the cytoskeleton

The "PTPN4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTPN4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

PTPN5 | PTPN6 | PTPN7 | PTPN9 | PTPRA | PTPRB | PTPRC | PTPRCAP | PTPRD | PTPRE | PTPRF | PTPRG | PTPRH | PTPRJ | PTPRK | PTPRM | PTPRN | PTPRN2 | PTPRN2-AS1 | PTPRO | PTPRQ | PTPRR | PTPRS | PTPRT | PTPRU | PTPRVP | PTPRZ1 | PTRH1 | PTRH2 | PTRHD1 | PTS | PTTG1 | PTTG1IP | PTTG2 | PTTG3P | PTX3 | PTX4 | PUDP | PUDPP2 | PUF60 | PUM1 | PUM2 | PUM3 | PURA | PURB | PURG | PURPL | PUS1 | PUS10 | PUS3 | PUS7 | PUS7L | PUSL1 | Putative POM121-like protein 1 | Putative uncharacterized protein C12orf63 | PVALB | PVALEF | PVR | PVRIG | PVT1 | PWAR1 | PWAR4 | PWAR5 | PWAR6 | PWARSN | PWP1 | PWP2 | PWRN1 | PWRN2 | PWRN3 | PWWP2A | PWWP2B | PWWP3A | PWWP3B | PXDC1 | PXDN | PXDNL | PXK | PXMP2 | PXMP4 | PXN | PXN-AS1 | PXT1 | PXYLP1 | PYCARD | PYCR1 | PYCR2 | PYCR3 | PYDC1 | PYDC2 | PYDC2-AS1 | PYGB | PYGL | PYGM | PYGO1 | PYGO2 | PYHIN1 | PYM1 | PYROXD1 | PYROXD2